

# Álvaro Díaz-González

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8909231/publications.pdf>

Version: 2024-02-01

28  
papers

499  
citations

687220

13  
h-index

677027

22  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2016, 34, 597-602.	0.8	72
2	Comparison of Capsule Endoscopy and Magnetic Resonance Enterography for the Assessment of Small Bowel Lesions in Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 775-780.	0.9	56
3	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology, 2018, 67, 612-622.	3.6	55
4	Controversies in the management of hepatocellular carcinoma. JHEP Reports, 2019, 1, 17-29.	2.6	45
5	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology and Therapeutics, 2019, 49, 482-491.	1.9	40
6	Surveillance for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 1001-1010.	1.0	25
7	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 710-719.	0.2	25
8	Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?. Liver Cancer, 2021, 10, 545-560.	4.2	22
9	New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transplantation, 2019, 25, 311-322.	1.3	21
10	Prognosis prediction and staging. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 855-865.	1.0	20
11	Endoscopic Retrograde Cholangiography for Biliary Anastomotic Strictures After Liver Transplantation. Clinics in Liver Disease, 2014, 18, 913-926.	1.0	19
12	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	1.3	19
13	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	1.9	15
14	New challenges in clinical research on hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas, 2015, 108, 485-93.	0.1	12
15	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. Journal of Hepatology, 2021, 74, 966-967.	1.8	12
16	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules $\geq 2$ cm in cirrhotic patients. European Radiology, 2021, 31, 4794-4803.	2.3	8
17	Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia. Hepatology, 2022, 76, 1259-1274.	3.6	8
18	Riesgo de recurrencia del carcinoma hepatocelular en pacientes tratados con antivirales libres de interferón. Gastroenterología Y Hepatología, 2019, 42, 502-511.	0.2	7

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	1.9	6
20	The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. <i>Oncotarget</i> , 2017, 8, 106151-106152.	0.8	5
21	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 263-270.	1.1	3
22	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 655-661.	1.6	2
23	Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma. <i>Hepatology</i> , 2018, 68, 2042-2044.	3.6	1
24	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021, 12, 440-449.	0.8	1
25	Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. <i>Current Hepatology Reports</i> , 2015, 14, 32-39.	0.4	0
26	La difusi3n del conocimiento en hepatologÁa en tiempos de cambio o por quÁ© deberÁas estar en Twitter. <i>GastroenterologÁa Y HepatologÁa</i> , 2021, 44, 388-393.	0.2	0
27	Budesonide in the first line treatment of patients with autoimmune hepatitis. <i>GastroenterologÁa Y HepatologÁa</i> , 2021, , .	0.2	0
28	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 141-152.	0.4	0